Todd C. Brady's Insider Trades & SAST Disclosures
Todd C. Brady's most recent trade in Evoke Pharma Inc was a trade of 1,187 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Todd C. Brady.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,187 | 8,238 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 809,710 | 809,710 | - | - | Stock Option (right to buy) | |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 14,625 | 14,625 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2024 | 1,081,201 | 1,081,201 | - | - | Stock Option (right to buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.27 per share. | 09 Mar 2024 | 97,914 | 1,556,622 (5%) | 0% | 3.3 | 320,521 | Common Stock |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 09 Mar 2024 | 85,324 | 1,471,298 (5%) | 0% | 3.0 | 260,238 | Common Stock |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 14,625 | 14,625 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 238,750 | 1,455,285 (5%) | 0% | 0 | Common Stock | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 604,308 | 604,308 | - | - | Bonus Units | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 23 Jun 2022 | 17,700 | 1,216,535 (4%) | 0% | 3.4 | 59,546 | Common Stock |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 57,750 | 57,750 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 250,000 | 250,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 46,619 | 948,835 (3%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges